Replies to post #218250 on Biotech Values

[DewDiligence]

More on COCP’s quest for a shorter HCV regimen:

https://globenewswire.com/news-release/2018/10/08/1617926/0/en/Cocrystal-Pharma-Announces-Clinical-Trial-Agreement-for-Investigator-Initiated-Phase-2a-Study-in-Hong-Kong-of-CC-31244-for-Ultra-Short-Treatment-of-Hepatitis-C-Virus.html

This is a single-arm IST in Hong Kong.

[DewDiligence]

COCP continues quest to find a 6w HCV regimen:

https://finance.yahoo.com/news/cocrystal-pharma-provides-clinical-development-130000390.html

The U.S. Phase 2a study is an open-label study designed to evaluate the safety, tolerability, and preliminary efficacy of CC-31244 with Epclusa in 12 subjects with treatment-naïve HCV genotype 1. Subjects received oral 400 mg of CC-31244 and Epclusa for 2 weeks. Following this, the subjects continued Epclusa treatment alone for another 4 weeks.

All subjects completed the 6-week treatment regimen. The treatment was well tolerated with no study discontinuations due to adverse events. Eight of 12 subjects the primary efficacy endpoint of sustained virologic response at 12 weeks after completion of treatment (SVR12).

So, SVR12 was 8/12 (66.7%), which is pretty strong evidence that investors shouldn’t consider this to be a serious program.

I’ve previously commented on the lack of a business impetus for a 6w HCV regimen.